Cystic Fibrosis Therapeutics Market Size in 2021 to Garner $9.27 Billion Globally by 2026
Pune, Maharashtra, India, February 9 2021 (Wiredrelease) Allied Analytics –:Increase in incidence of cystic fibrosis and advancements in therapeutics for treatment of cystic fibrosis have boosted the growth of the global cystic fibrosis therapeutics market. However, less awareness in developing nations impedes the growth to certain extent. On the contrary, rise in R&D towards the development of novel therapeutics is expected to create lucrative opportunities in the near future.
“Cystic Fibrosis (CF) Therapeutics Market by Drug Class (Pancreatic Enzyme Supplements, Mucolytic, Bronchodilators, and CFTR Modulators) and Route of Administration (Oral and Inhaled): Global Opportunity Analysis and Industry Forecast, 2019-2026″. According to the report, the global cystic fibrosis therapeutics industry was pegged at $4.61 billion in 2018 and is estimated to reach $9.27 billion by 2026, registering a CAGR of 9.2% from 2019 to 2026.
Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/5499
The global cystic fibrosis therapeutics market across North America is expected to register the fastest CAGR of 9.9% during the forecast period. This is attributed to the presence of key market players of cystic fibrosis in this region. On the other hand, the Europe region held the largest share in 2018, accounting for nearly two-fifths of the market. The region is expected to dominate the market throughout the forecast period. This is due to increase in incidence of cystic fibrosis, rise in governmental support for innovation and surge in funding of projects for R&D of various cystic fibrosis drugs.
Dairy CFTR modulators segment to portray the fastest growth :–
Based on drug class, the CFTR modulators segment dominated the global cystic fibrosis therapeutics market in 2018, contributing to nearly two-thirds of the market. The segment is expected to maintain its dominance throughout the forecast period. Moreover, the segment is projected to register the fastest CAGR of 9.9% during the forecast period. This is due rise in usage of these drugs for the treatment of cystic fibrosis.
Inhale segment dominated the market :–
Based on route of administration, the inhale segment held the largest share in 2018, contributing to nearly three-fifth of the global cystic fibrosis therapeutics market. The segment is expected to maintain its dominance throughout the study period. As inhaler therapeutics help patients in proper breathing by diluting the mucus. However, the oral segment is projected to manifest the fastest CAGR of 9.9% during the study period. This is attributed to increased formulation of drugs in oral form such as development of CFTR drugs.
For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/5499
Key players operating in cystic fibrosis therapeutic markets are Genentech, Inc., Novartis AG, Gilead Sciences, Inc., Vertex Pharmaceuticals Incorporated, AbbVie Inc., GlaxoSmithKline Plc., Johnson & Johnson, Allergan plc, Pharmaxis Ltd., and Mylan N.V.
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
This content has been published by Allied Analytics company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at email@example.com.